Compare COOK & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COOK | NKTX |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.2M | 132.8M |
| IPO Year | 2021 | 2020 |
| Metric | COOK | NKTX |
|---|---|---|
| Price | $0.85 | $2.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $2.04 | ★ $13.25 |
| AVG Volume (30 Days) | 251.6K | ★ 701.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.29 | 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $604,072,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.71 | $1.31 |
| 52 Week High | $2.42 | $2.74 |
| Indicator | COOK | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.66 | 72.33 |
| Support Level | $0.85 | $1.95 |
| Resistance Level | $1.05 | $2.74 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 50.35 | 98.00 |
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.